OceanIQ Capital LLC Buys New Position in Zoetis Inc. $ZTS

OceanIQ Capital LLC acquired a new position in Zoetis Inc. (NYSE:ZTS) during the 2nd quarter, HoldingsChannel.com reports. The fund acquired 11,208 shares of the company’s stock, valued at approximately $845,000.

Several other institutional investors have also added to or reduced their stakes in ZTS. BlackRock Inc. lifted its position in Zoetis by 10.8% in the 2nd quarter. BlackRock Inc. now owns 39,430,181 shares of the company’s stock worth $2,833,453,000 after buying an additional 3,845,869 shares during the last quarter. J. Stern & Co. LLP increased its position in Zoetis by 12,431.2% during the 4th quarter. J. Stern & Co. LLP now owns 24,069,492 shares of the company’s stock valued at $3,028,423,000 after purchasing an additional 23,877,416 shares during the period. State Street Corp raised its position in shares of Zoetis by 0.8% in the 4th quarter. State Street Corp now owns 19,796,891 shares of the company’s stock worth $2,490,845,000 after acquiring an additional 149,382 shares in the last quarter. Geode Capital Management LLC raised its holdings in Zoetis by 1.7% in the fourth quarter. Geode Capital Management LLC now owns 11,327,679 shares of the company’s stock worth $1,420,294,000 after purchasing an additional 189,235 shares in the last quarter. Finally, Deutsche Bank AG increased its stake in shares of Zoetis by 5.8% during the second quarter. Deutsche Bank AG now owns 5,851,737 shares of the company’s stock valued at $420,506,000 after purchasing an additional 319,709 shares in the last quarter. 92.80% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities research analysts have commented on ZTS shares. Stifel Nicolaus dropped their target price on Zoetis from $85.00 to $80.00 and set a “hold” rating on the stock in a report on Thursday, August 20th. Argus reiterated a “hold” rating on shares of Zoetis in a research note on Wednesday, May 27th. HSBC decreased their price objective on shares of Zoetis from $140.00 to $95.00 and set a “buy” rating for the company in a report on Monday, July 6th. BNP Paribas Exane reduced their price objective on Zoetis from $146.00 to $110.00 and set an “outperform” rating for the company in a report on Tuesday, August 11th. Finally, Piper Sandler decreased their target price on Zoetis from $90.00 to $80.00 and set a “neutral” rating for the company in a research report on Monday, August 10th. Eight equities research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Hold” and an average target price of $107.43.

Zoetis Price Performance

Zoetis stock opened at $75.70 on Friday. The firm has a 50-day moving average of $75.53 and a two-hundred day moving average of $93.85. The stock has a market cap of $31.28 billion, a price-to-earnings ratio of 12.47, a price-to-earnings-growth ratio of 1.78 and a beta of 0.73. Zoetis Inc. has a 1 year low of $71.00 and a 1 year high of $155.15. The company has a debt-to-equity ratio of 2.87, a current ratio of 3.08 and a quick ratio of 1.84.

Zoetis (NYSE:ZTS) last issued its earnings results on Thursday, August 6th. The company reported $1.87 earnings per share for the quarter, topping the consensus estimate of $1.85 by $0.02. Zoetis had a return on equity of 74.89% and a net margin of 27.49%.The business had revenue of $2.47 billion during the quarter, compared to analysts’ expectations of $2.50 billion. During the same period in the prior year, the business earned $1.76 EPS. The business’s revenue for the quarter was down .2% compared to the same quarter last year. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. On average, research analysts forecast that Zoetis Inc. will post 6.2 earnings per share for the current year.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.